{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:42:04Z","timestamp":1792021324867,"version":"4.4.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,7,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Levofloxacin prophylaxis (LVXp) is often used for patients with underlying leukemia and severe neutropenia to reduce the risk of fever and bacteremia. This study evaluated trends in viridans group streptococci (VGS) antibiotic susceptibilities over time and clinical outcomes of children with VGS bloodstream infections (BSIs) during institutional adoption of LVXp.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>VGS blood culture isolates between 1\/1\/2010 and 12\/31\/2021 with susceptibility testing reported were included. Available isolates were re-identified to the species level and additional susceptibility testing was performed. Demographic and clinical data were abstracted from medical records.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 264 VGS BSI isolates were identified in immunocompromised (IC, n = 125) and non-immunocompromised subjects, (non-IC, n = 139). IC subjects had lower rates of VGS isolates susceptible (S) to LVX and higher minimum inhibitory concentration (MICs) to LVX (p = 0.004) and ciprofloxacin (p = 0.0005) compared with non-IC subjects. No other evaluated antibiotic had increased MICs in either group. Fifteen of 19 (74%) LVX not susceptible (NS) isolates occurred in IC subjects, 13 represented breakthrough infections. IC subjects had higher rates of VGS-related shock (p = 0.012), need for pressor support (p = 0.039), and longer duration of hospitalization than non-IC subjects (p &amp;lt; 0.001). Clinical outcomes were comparable between subjects with LVX S and NS VGS BSI isolates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>VGS with reduced susceptibility to LVX emerged during institutional adoption of LVXp in high-risk children with immunocompromising conditions, but did not result in significant differences in clinical outcomes. Ongoing surveillance and susceptibility testing are critical in weighing the utility of LVXp against emerging antimicrobial resistance in this high-risk population.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpids\/piad041","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T16:53:33Z","timestamp":1690304013000},"page":"381-391","source":"Crossref","is-referenced-by-count":12,"title":["Emerging Resistance Trends in Viridans Group Streptococci Bloodstream Infections Among Immunocompromised Children Receiving Levofloxacin Prophylaxis"],"prefix":"10.1093","volume":"12","author":[{"given":"Ana M","family":"Quintero","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Nationwide Children\u2019s Hospital , Columbus, Ohio , USA"},{"name":"Department of Pediatrics, The Ohio State University College of Medicine , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A","family":"Cruz Vidal","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Nationwide Children\u2019s Hospital , Columbus, Ohio , USA"},{"name":"Department of Pediatrics, The Ohio State University College of Medicine , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett G","family":"Klamer","sequence":"additional","affiliation":[{"name":"Biostatistics Resource at Nationwide Children\u2019s Hospital (BRANCH), Nationwide Children\u2019s Hospital , Columbus, Ohio , USA"},{"name":"Center for Biostatistics, The Ohio State University , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica I","family":"Ardura","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Nationwide Children\u2019s Hospital , Columbus, Ohio , USA"},{"name":"Department of Pediatrics, The Ohio State University College of Medicine , Columbus, Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9372-3491","authenticated-orcid":false,"given":"Sophonie J","family":"Oyeniran","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Nationwide Children\u2019s Hospital, The Ohio State University Wexner Medical Center Columbus , Ohio , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"key":"2023091811594176400_CIT0001","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1200\/JCO.2000.18.9.1845","article-title":"Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the children\u2019s cancer group study CCG-2891","volume":"18","author":"Gamis","year":"2000","journal-title":"J Clin Oncol"},{"key":"2023091811594176400_CIT0002","doi-asserted-by":"crossref","first-page":"e28234","DOI":"10.1002\/pbc.28234","article-title":"Mucosal barrier injury-associated bloodstream infections in pediatric oncology patients","volume":"67","author":"Hakim","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"2023091811594176400_CIT0003","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1097\/MPH.0000000000001814","article-title":"Pediatric febrile neutropenia: change in etiology of bacteremia, empiric choice of therapy and clinical outcomes","volume":"42","author":"Alali","year":"2020","journal-title":"J Pediatr Hematol Oncol"},{"key":"2023091811594176400_CIT0004","doi-asserted-by":"crossref","first-page":"e160","DOI":"10.1097\/MPH.0000000000002258","article-title":"Bloodstream infections in children with cancer: pathogen distribution and antimicrobial susceptibility patterns over a 10-year period","volume":"44","author":"Maarbjerg","year":"2022","journal-title":"J Pediatr Hematol Oncol"},{"key":"2023091811594176400_CIT0005","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1200\/JCO.2004.09.108","article-title":"Predictors of viridans streptococcal shock syndrome in bacteremic children with cancer and stem-cell transplant recipients","volume":"22","author":"Gassas","year":"2004","journal-title":"J Clin Oncol"},{"key":"2023091811594176400_CIT0006","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0022-3476(78)80040-7","article-title":"Streptococcus salivarius sepsis in children with malignancies","volume":"92","author":"Hoecker","year":"1978","journal-title":"J Pediatr"},{"key":"2023091811594176400_CIT0007","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1086\/340402","article-title":"Infections caused by viridans streptococci in patients with neutropenia","volume":"34","author":"Tunkel","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0008","doi-asserted-by":"crossref","first-page":"e2952","DOI":"10.1097\/MD.0000000000002952","article-title":"Viridans group streptococcal infections in children after chemotherapy or stem cell transplantation: a 10-year review from a tertiary pediatric hospital","volume":"95","author":"Nielsen","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"2023091811594176400_CIT0009","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s15010-013-0470-7","article-title":"Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropenia","volume":"41","author":"Han","year":"2013","journal-title":"Infection"},{"key":"2023091811594176400_CIT0010","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/1471-2334-13-273","article-title":"Clinical characteristics and antimicrobial susceptibilities of viridans streptococcal bacteremia during febrile neutropenia in patients with hematologic malignancies: a comparison between adults and children","volume":"13","author":"Han","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2023091811594176400_CIT0011","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1056\/NEJMoa044097","article-title":"Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia","volume":"353","author":"Bucaneve","year":"2005","journal-title":"N Engl J Med"},{"key":"2023091811594176400_CIT0012","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1001\/jama.2018.12512","article-title":"Effect of levofloxacin prophylaxis on bacteremia in children with acute leukemia or undergoing hematopoietic stem cell transplantation: a randomized clinical trial","volume":"320","author":"Alexander","year":"2018","journal-title":"JAMA"},{"key":"2023091811594176400_CIT0013","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0014","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/cid\/ciz1082","article-title":"Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation","volume":"71","author":"Lehrnbecher","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0015","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/0002-9343(94)90009-4","article-title":"Bacteremia due to viridans streptococci in neutropenic patients: a review","volume":"97","author":"Bochud","year":"1994","journal-title":"Am J Med"},{"key":"2023091811594176400_CIT0016","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1053\/j.spid.2006.06.008","article-title":"Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance","volume":"17","author":"Bruckner","year":"2006","journal-title":"Semin Pediatr Infect Dis"},{"key":"2023091811594176400_CIT0017","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/00365549709019036","article-title":"Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis","volume":"29","author":"Spanik","year":"1997","journal-title":"Scand J Infect Dis"},{"key":"2023091811594176400_CIT0018","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"CLSI","year":"2021","edition":"31"},{"key":"2023091811594176400_CIT0019","doi-asserted-by":"crossref","first-page":"e0120502","DOI":"10.1371\/journal.pone.0120502","article-title":"Viridans Group streptococci clinical isolates: MALDI-TOF mass spectrometry versus gene sequence-based identification","volume":"10","author":"Angeletti","year":"2015","journal-title":"PLoS One"},{"key":"2023091811594176400_CIT0020","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s10096-013-2012-8","article-title":"Evaluation of two matrix-assisted laser desorption ionization-time of flight mass spectrometry systems for identification of viridans group streptococci","volume":"33","author":"Karpanoja","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2023091811594176400_CIT0021","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.mimet.2015.03.020","article-title":"Comparative evaluation of two matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) systems, Vitek MS and Microflex LT, for the identification of Gram-positive cocci routinely isolated in clinical microbiology laboratories","volume":"113","author":"Lee","year":"2015","journal-title":"J Microbiol Methods"},{"key":"2023091811594176400_CIT0022","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1086\/428052","article-title":"Mechanisms of resistance to quinolones","volume":"41","author":"Jacoby","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0023","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.inf.0000164708.21464.03","article-title":"Viridans streptococci bacteremia in children with malignancy: relevance of species identification and penicillin susceptibility","volume":"24","author":"Husain","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"2023091811594176400_CIT0024","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1128\/JCM.01563-10","article-title":"It\u2019s not easy being green: the viridans group streptococci, with a focus on pediatric clinical manifestations","volume":"48","author":"Doern","year":"2010","journal-title":"J Clin Microbiol"},{"key":"2023091811594176400_CIT0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jinf.2013.12.006","article-title":"Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients","volume":"68","author":"Mikulska","year":"2014","journal-title":"J Infect"},{"key":"2023091811594176400_CIT0026","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1017\/ice.2017.57","article-title":"A prospective, holistic, multicenter approach to tracking and understanding bloodstream infections in pediatric hematology-oncology patients","volume":"38","author":"Gaur","year":"2017","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2023091811594176400_CIT0027","doi-asserted-by":"crossref","first-page":"979","DOI":"10.7326\/0003-4819-142-12_Part_1-200506210-00008","article-title":"Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients","volume":"142","author":"Gafter-Gvili","year":"2005","journal-title":"Ann Intern Med"},{"key":"2023091811594176400_CIT0028","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1093\/cid\/ciab404","article-title":"Colonization with fluoroquinolone-resistant Enterobacterales decreases the effectiveness of fluoroquinolone prophylaxis in hematopoietic cell transplant recipients","volume":"73","author":"Satlin","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0029","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1086\/314054","article-title":"In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: data from the SENTRY antimicrobial surveillance program","volume":"31","author":"Jones","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0030","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.ijantimicag.2014.01.031","article-title":"Species-level assessment of the molecular basis of fluoroquinolone resistance among viridans group streptococci causing bacteraemia in cancer patients","volume":"43","author":"Sahasrabhojane","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2023091811594176400_CIT0031","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1086\/340352","article-title":"Bacteremia due to viridans group streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis","volume":"34","author":"Razonable","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0032","doi-asserted-by":"crossref","first-page":"e29525","DOI":"10.1002\/pbc.29525","article-title":"Levofloxacin prophylaxis for pediatric leukemia patients: longitudinal follow-up for impact on health care-associated infections","volume":"69","author":"Davis","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2023091811594176400_CIT0033","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/INF.0000000000000058","article-title":"Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group","volume":"33","author":"Lewis","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"2023091811594176400_CIT0034","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/JCM.44.1.160-165.2006","article-title":"Viridans streptococci isolated by culture from blood of cancer patients: clinical and microbiologic analysis of 50 cases","volume":"44","author":"Han","year":"2006","journal-title":"J Clin Microbiol"},{"key":"2023091811594176400_CIT0035","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciy825","article-title":"Fluoroquinolone prophylaxis selects for meropenem-nonsusceptible Pseudomonas aeruginosa in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"68","author":"Hakki","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0036","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1016\/j.bbmt.2020.03.027","article-title":"Fluoroquinolone prophylaxis in autologous stem cell transplantation: worthy of a second look","volume":"26","author":"Maakaron","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023091811594176400_CIT0037","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/cid\/ciab1000","article-title":"Cessation of ciprofloxacin prophylaxis in haemato-oncology patients","volume":"75","author":"Caldwell","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023091811594176400_CIT0038","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3947\/ic.2022.0005","article-title":"Bacteremia in hematopoietic stem cell recipients receiving fluoroquinolone prophylaxis: incidence, resistance, and risk factors","volume":"54","author":"Eryilmaz-Eren","year":"2022","journal-title":"Infect Chemother"},{"key":"2023091811594176400_CIT0039","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","article-title":"Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines","volume":"76","author":"Mikulska","year":"2018","journal-title":"J Infect"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piad041\/50959263\/piad041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/12\/7\/381\/51658725\/piad041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/12\/7\/381\/51658725\/piad041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T12:42:47Z","timestamp":1695040967000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/12\/7\/381\/7230767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,25]]},"published-print":{"date-parts":[[2023,7,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piad041","relation":{},"ISSN":["2048-7207"],"issn-type":[{"value":"2048-7207","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,7,31]]},"published":{"date-parts":[[2023,7,25]]}}}